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INTRODUCTION
The process of developing new anticancer therapeu-
tics has been considered by some to be expensive,1
time consuming,2 bureaucratic,3 and, to some extent,
inefficient.4 The coronavirus disease 2019 (COVID-19)
pandemic has significantly affected clinical oncology
studies5,6 and underlined the need to embrace and
accelerate long-pending and awaited reforms to
cancer clinical trial methodology.7-9
This article highlights the need for optimal use of
technology, reduced paperwork and bureaucracy,
speedier trial setup, and greater patient centricity in
the design and conduct of future clinical and trans-
lational cancer studies around the world.
INCREASED USE OF TECHNOLOGY
The basic technology to enable secure and reliable
telephone/video contact between clinicians, study
coordinators, and patients to facilitate remote medical
consultation has been available for a number of years;
however, its adoption has been limited for a variety of
reasons, including lack of access to such technologies
in some developing countries and concerns sur-
rounding privacy, safety, financial reimbursement,
and legal and regulatory issues. Changes to reim-
bursement rules and regulations have been recently
announced to encourage the use of telemedicine
during the COVID-19 lockdown.10,11 These and other
such pandemic-era reforms should be adopted not
only for the current situation but should also be
considered for permanent adoption.12-14
Electronic consent and telemedicine consultation
could replace some protocol-mandated clinic visits,
especially those for which medical imaging, biosample
collection, or physical examination are not required.15
Reduced exposure to the hospital environment could
enhance patient safety, comfort, and quality of life
while also perhaps lowering the number of protocol
deviations in clinical trials and the overall burden of
trial participation.16 It may also help reduce in-
equalities in access to clinical trials resulting from
transportation challenges because of geographic,
financial, or physical issues, and would also reduce the
burden on patient caregivers. Virtual formats could
replace in-person investigator meetings, steering
committee meetings, etc, thereby reducing physical,
financial, and environmental burden while increasing
speed and flexibility. Using social media as an easily
accessible communication tool could also help to
optimize the care of patients enrolled in cancer clinical
trials.17 Measures that can be self-reported by patients
are increasingly being used in clinical practice and
trials, and these data can be collected remotely as
electronic patient-reported outcomes (ePROs).
During the ongoing pandemic, patients, clinicians,
and hospitals have become increasingly comfortable
using telemedicine, and many stakeholders agree that
the resulting improved access, lower cost, reduced risk
of infection, and time saved should make telemedicine
an integral part of our standard practice in cancer care
and research moving forward, at least for predefined
activities.18,19 Adopting digital pathology and radiomics
platforms to enable images to be seamlessly analyzed
at a remote and/or central facility could increase ef-
ficiency in cancer trials.20,21
Use of artificial intelligence could help efficiently
match the unique clinical and molecular pathology
characteristics of a given patient to relevant clinical
trials within their region of the country,22,23 thereby
providing access to potentially life-enhancing trials for
a broader and more diverse population.24
Physical activity trackers, smart watches and other
wearable devices, and smartphones with health ap-
plications allow for the real-time remote collection
of health parameters, such as physical activity,
ECG, temperature, blood glucose level,25 oxygen
saturation,26 and ePROs.27 Validated, secure, and
approved wearable devices could autopopulate trial
databases with robust longitudinal data, reducing the
need for manual data entry and providing more effi-
cient and improved data quality and integrity.28 Use of
clinical decision support algorithms to detect early
signs and symptoms of concern (eg, fever and
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treating clinical team should be explored in cancer clinical
trials where feasible.29 Such algorithms can also be cus-
tomized to support specific clinical trial protocols, which
may help to improve protocol adherence and care con-
sistency across investigators in decentralized sites so that
clinical trials can be opened in additional community sites
and be more accessible for more patients closer to
their homes.
Remote monitoring by contract research organization staff,
other auditors, and even by regulatory inspectors could also
be enabled by secure technologic solutions.30,31
We should acknowledge, however, that there are chal-
lenges to the increased use of such technologies in clinical
trials, especially related to cybersecurity. It is also im-
portant to ensure that the increased use of technology
does not have the unintended consequence of excluding
individuals who are unable or unwilling to access that
technology, such as the elderly and disadvantaged.
Moreover, the increased use of technology may be both an
opportunity and a threat to increasing clinical trial par-
ticipation by people in low- and middle-income countries
where access to mobile devices may be relatively good but
other infrastructure less so.
Cutting the Clutter
Eliminating unnecessary complexity and bureaucracy from
clinical trials could help reduce the cost and time required
to answer research questions.32,33
Reducing the verbosity and complexity of the informed
consent form is long overdue.34,35 In case patients who
are enrolled in ongoing studies need to have their consent
reobtained, the updated informed consent forms should
not repeat information already presented in the initial
consent documents, and the application of eConsent
technologies provides an efficient source of this re-
vised information and an effective audit of review and
signature.
Each data item that is collected in clinical trials generates
burden and cost (data entry, multiple levels of checks,
source data verification, and query generation and reso-
lution). Despite this, a significant proportion of the data
collected during cancer trials may never be used; for ex-
ample, a Canadian study found that only 18% of data el-
ements collected during clinical trials were reported in
future publications,36 although a part of such unpublished
data may still have been used effectively.
Whereas the collection of research biopsies may enable
useful future correlative science, their immediate utility
often remains uncertain.37 A strong scientific rationale for
collecting tissue should be defined and ethical issues
should be carefully considered before making them
mandatory in cancer trials.38 Alternate specimen types,
such as liquid biopsies, for enrollment or monitoring pur-
poses should be considered when and where appropriate.
The process of submitting diagnostic blocks and other
biosamples should be streamlined and standardized,39 and
we should aim to collect only the essential data and
samples required to answer the predefined objectives of the
ongoing study, allowing the option to collect more data
and samples from interested patients/sites for subsequent
translational research.
Published and reusable standards, rather than just tem-
plates, of trial charters, biospecimen collection protocols,
and toxicity management guidelines could help reduce
paperwork and duplication of effort. Attempts at the
standardization of trial methodology should be encouraged
and adopted.40 A greater ease of administration for ethical
review across institutions, which would allow for a single
ethics board to be designated lead for multiple centers
within a region, country, or even continent, should become
standard.
Regulators, such as the US Food and Drug Administra-
tion41; health systems, like the United Kingdom National
Health Service42; professional oncology societies, such
as the European Society of Medical Oncology and the
American Society of Clinical Oncology30,43; academicians;
and industry should continue to make efforts to streamline
clinical research and reduce the burden of paperwork.44 It
is a challenge for principal investigators to sign off and act
as guarantor for electronic case record forms and multiple
serious adverse event reports; it is important that investi-
gator oversight is not diluted by collecting ever-increasing
volumes of data for which they are not easily equipped to
vouch and certify.
Speedier Approvals and Permissions to Launch
Clinical Trials
Regulators and stakeholders involved with planning and
executing cancer studies should carefully analyze and
adopt best practices where possible from some large
COVID-19 trials, like RECOVERY (EudraCT 2020-001113-
21), DisCoVeRy (ClinicalTrials.gov identifier: NCT04315948),
and SOLIDARITY (ClinicalTrials.gov identifier: NCT04330690),
which were designed quickly and built to greatly reduce
the bureaucratic burden on participating sites, with rapid
startup, simplified requirements for recording consent,
collection of only essential data, and ease and flexibility in
methods of data entry, which enabled a remarkably early
first readout of efficacy.45
Patient Centricity
With numerous societal changes underway, this is also an
opportunity for a step change in patient involvement in
clinical trials. Much progress has been made with patient
and public involvement in clinical trials, grant applications,
and trial oversight groups. Still, there is scope for deeper
engagement with patient and public involvement groups to
set the global oncology research agenda. Such a relation-
ship must be transparent and integral to study design and
conduct and not merely superficial. Many COVID-19 trials
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had broad entry criteria, and there is now an opportunity
similarly to broaden eligibility criteria46,47 and to recruit an
ethnically diverse population in cancer trials.48
The COVID-19 pandemic has given a boost to the
emerging concept of the virtual or decentralized trial,
which is a siteless study in which patient recruitment is
done via Web-based methods that involve social media,
patient portal and telemedicine applications, informed
consent via remote electronic document access, review
and signature, some trial activities done via video con-
ference, physical examination done via remote visit or in-
home nurse visit, laboratory specimen collection done by local
clinics or in-home phlebotomist visit or patient service draw
centers, data collection via digital health devices or ePROs,
shipping of drugs to the patient’s home, and outcomes col-
lected by remote methods using digital tools.49 A fully virtual
trial is not feasible for most cancer studies, given the need for
detailed and often delicate discussions, especially at the time
of informed consent50; intravenous drug administrations;
medical imaging; and toxicity surveillance. However,
decentralizing some elements when appropriate could make
conventional trials more efficient, potentially reducing patient
burden and consequential clinical trial dropout and optimizing
health care resource utilization. These hybrid trials would be
located on a spectrum, with interventional clinical trials at one
end and pragmatic or real-world studies at the other.51 A
careful review of the number ofmandatory visits to the hospital
should be performed and, where possible, reduced.8 Social
media platforms should be used to share results of clinical
trials in innovative and patient-centered ways, including lay-
language summaries and intuitive data visualization.
Future Perspectives
The coming era of more patient-friendly clinical trials will
require changes to the way cancer services are currently
organized and delivered, with the aim of reducing the
number of times the patient and contract research orga-
nization staff need to visit the site. Home visits by spe-
cialized nurses and phlebotomists, delivery of certain
medications to patients’ homes, and precise and timely
communication with family physicians or local clinics to
perform laboratory testing will likely improve the patient
experience. It will, however, require careful coordination by
the sites, which could be challenging in areas with limited
capacity or resources. We must also be careful to ensure
that any changes we adopt should not result in the sys-
tematic exclusion of potential patient pools based on
geographic location, rural versus urban settings, access to
digital technology, educational level, ethnicity, ability, or
age.52,53
In conclusion, the pandemic has revealed certain limita-
tions in the current models of cancer care and the tradi-
tional conservative approach to cancer research.54-56
Consequently, the move toward patient centricity has
accelerated, with increasing use of easily accessible and
comprehensible technology, such as video, mobile phones,
apps, telemedicine, and wearable devices. It has also
created an opportune moment to reflect on past practices
and fine tune the technologies, policies, andmethodologies
that we adopt in future cancer studies to enable us to
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